Johnson & Johnson: Mental Disorders trials
The registry lists 21 Mental Disorders studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 2 have results posted.
Phase 1 1Phase 3 16Phase 4 2No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or SchizophreniformCompletedNCT02431702Phase 3Results posted
- A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in ChildrenCompletedNCT01050582Phase 4Results posted
- Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric ParticipantsCompletedNCT02087579Phase 1
- Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of PsychosisCompletedNCT00369239Phase 4
- A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I DisorderCompletedNCT00309686Phase 3
- A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR)CompletedNCT00294008
- A Survey Study of the Treatment and Outcome Management in Patients Diagnosed With Alzheimer's DiseaseCompletedNCT00291421
- A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental RetardationCompletedNCT00266552Phase 3
- A Prospective Study of Risperdal (Risperidone) for the Treatment of Behavioral Disorder Following Psychological Therapy for Challenging Behavior in Learning Disabled ChildrenCompletedNCT00254930Phase 3
- A Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With SchizophreniaCompletedNCT00253136Phase 3
- A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental RetardationCompletedNCT00250354Phase 3
- A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic SchizophreniaCompletedNCT00249223Phase 3
- A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic SchizophreniaCompletedNCT00249132Phase 3
- A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic SchizophreniaCompletedNCT00249119Phase 3
- A Study of the Effectiveness and Safety of Topiramate in the Treatment of Patients With Bipolar DisorderCompletedNCT00240721Phase 3
- A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive ImpairmentCompletedNCT00240695Phase 3
- A Study of the Safety of Risperidone in the Treatment of Children and Adolescents With Conduct and Other Disruptive Behavior DisordersCompletedNCT00236470Phase 3
- A Study of the Efficacy and Safety of Risperidone in the Prevention of Relapse in Children and Adolescents With Conduct and Other Disruptive Behavior DisordersCompletedNCT00236444Phase 3
- A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's DiseaseCompletedNCT00216502Phase 3
- A Study to Evaluate the Safety and Effectiveness of Topiramate Compared to Placebo in the Treatment of Patients With Bipolar I DisorderCompletedNCT00035802Phase 3
- Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's DiseaseCompletedNCT00034762Phase 3